Skip to main content
Launch offer40% off your first paymentEnds 31 DecemberSee plans
Celea Therapeutics logo

Celea Therapeutics

Biotech & Pharmaceuticals
WebsiteLinkedIn

Celea Therapeutics is dedicated to advancing transformative treatments for people with serious respiratory diseases. Its lead program, deupirfenidone (LYT-100), is in Phase 3 development for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases.

Open roles
2
Headquarters
6 Tide Street, Suite 400, Boston, MA 02210

Follow Celea Therapeutics

Create an exact-company alert for on-site matches and optional daily email.

Open roles